RxDoctor Payments Data

Giang Nguyen, PA

Physician Assistant · Austin, TXNPI 1982097929

Payments from drug & device makers

$2,813in general payments, 2019–2025

Across 135 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$707
  • Johnson & Johnson$316
  • Amgen$315
  • GSK$307
  • Phathom Pharmaceuticals, Inc.$237
  • AstraZeneca$198
  • plus $734 from 10 others

What the payments were for

  • Food & beverage$2,813100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,813 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$74,250
Medicare patients
287
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$68,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$36,597
MounjaroTirzepatide22$24,475
JanuviaSitagliptin Phosphate12$18,986
LinzessLinaclotide18$13,296
Tresiba Flextouch U-100Insulin Degludec14$10,466
BelsomraSuvorexant17$7,493
SymbicortBudesonide/Formoterol Fumarate11$3,822
Icosapent Ethyl12$2,251
Levothyroxine Sodium190$2,100
Estradiol13$1,497
PaxlovidNirmatrelvir/Ritonavir21$1,429
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$1,402
Gabapentin58$960
Albuterol Sulfate HfaAlbuterol Sulfate35$954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$707$68,78947 claims
GSKTrelegy Ellipta$307$36,59758 claims
Lilly USA, LLCMounjaro$89$24,47522 claims
AbbVieLinzess$174$13,29618 claims
AstraZenecaSymbicort$198$3,82211 claims
PfizerPaxlovid$34$1,42921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →